Are you in a crisis? Call or text 988 to speak to a crisis counselor.

COVID Policy

Coronavirus (COVID-19) Notice

We want to assure you that the health and safety of our patients, their families, and our staff are a priority. We continue to closely monitor official information from the CDC and World Health Organization, as well as our state and local government initiatives within our community regarding COVID-19.

In addition, we will be implementing the following policies in each of our clinics:

Mask Optional Policy

Covid screenings on all patients entering the clinics

Temperature checks

Hand sanitizer is available throughout each clinic

Strict infection control measures, including sanitizing the following:

All patient care areas/infusion rooms

Hard surfaces

Waiting room

Door handles

Countertops

Provider offices

We ask that you follow all CDC guidelines when it comes to COVID-19 isolation and safety. You can read the current guidelines here. If you need to reschedule an appointment due to COVID-19, you can do so by calling or emailing us.

Currently, insurance companies do not typically cover Ketamine infusions. However, the landscape for treatment coverage is changing quickly, and we hope reimbursement will be available in the future.

Yes, Spravato is covered by insurance. Spravato is FDA-approved for treating Major Depressive Disorder with Suicidal thoughts and treatment-resistant depression.

We accept the following insurance:

  • Blue Cross Shield of Illinois PPO
  • Aetna PPO
  • Cigna PPO

For more information about IV Ketamine & Spravato coverage, please contact the clinic.

The National Institute of Mental Health (NIMH) conducted a significant study on Ketamine treatments. It indicated up to 70% of patients experienced relief after six Ketamine treatments. (This is much higher than traditional antidepressants, which take weeks to work and only have a 33% success rate.)

Ketamine has a solid 40-year track record and is used worldwide as an anesthetic, particularly for children. When administered by infusion for psychiatric treatment, it uses far lower doses than an anesthetic. 

APS has designed its Ketamine infusion protocols to effectively minimize the potential for tolerance or addiction. Although Ketamine is not proven to be addictive, it’s possible to develop a tolerance due to abuse.

It is important to accurately assess your response to treatment with Ketamine. This can be difficult if medication changes are occurring at the same time. Therefore, we recommend that no medication changes be made immediately before, during, or shortly after the infusion course if you already have a prescribing provider (i.e., psychiatrist, nurse practitioner, PCP).

Certain medications like benzodiazepines (Xanax, Clonazepam), lamotrigine, or MAO-I inhibitors, may require adjustments. APS’ medical providers will guide you on what changes to make and when.

A typical infusion course involves six treatments over 2 to 3 weeks. The response length varies between individuals. Some return regularly for infusions; others do not.

Some patients do not need additional Ketamine therapy after their initial six infusions. Other patients may come back at the 4-6 week mark post last treatment date. Your experience will be unique as responses vary from patient to patient.

It’s possible to feel improvement after the first infusion or at any point during the therapy. Most patients feel better after the third or fourth infusion. Results vary, and each patient experience is different.

It is a good idea to take the day off from regular activities after Ketamine infusion therapy. You will not be able to drive for the rest of the day following an infusion. You should also not operate heavy machinery and avoid making important decisions. You can return to these activities and your regular work schedule after a good night’s rest.